Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Multicenter Study to Test Progression-free and Overall Survival of CY-503 in the Treatment of Patients With Unresectable Stage IV Metastatic Melanoma After Antineoplastic Treatment Failure.

Trial Profile

A Phase II Multicenter Study to Test Progression-free and Overall Survival of CY-503 in the Treatment of Patients With Unresectable Stage IV Metastatic Melanoma After Antineoplastic Treatment Failure.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 24 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aviscumine (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Sponsors Cytavis BioPharma

Most Recent Events

  • 20 Apr 2016 Results presented at the 107th Annual Meeting of the American Association for Cancer Research
  • 22 Feb 2012 Planned number of patients changed from 29 to 32 as reported by European Clinical Trials Database.
  • 25 Aug 2011 New source identified and integrated (European Clinical Trials Database record, EudraCT2007-000427-17).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top